- Home
- TPST vs ASBP Comparison
TPST vs ASBP Comparison
Compare TPST & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- ASBP
- Stock Information
- Founded
- TPST 2011
- ASBP 2021
- Country
- TPST United States
- ASBP United States
- Employees
- TPST N/A
- ASBP N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- ASBP Health Care
- Exchange
- TPST Nasdaq
- ASBP Nasdaq
- Market Cap
- TPST 33.0M
- ASBP 26.6M
- IPO Year
- TPST N/A
- ASBP N/A
- Fundamental
- Price
- TPST $10.93
- ASBP $0.43
- Analyst Decision
- TPST Hold
- ASBP
- Analyst Count
- TPST 3
- ASBP 0
- Target Price
- TPST $30.00
- ASBP N/A
- AVG Volume (30 Days)
- TPST 83.5K
- ASBP 28.4M
- Earning Date
- TPST 08-11-2025
- ASBP 08-13-2025
- Dividend Yield
- TPST N/A
- ASBP N/A
- EPS Growth
- TPST N/A
- ASBP N/A
- EPS
- TPST N/A
- ASBP N/A
- Revenue
- TPST N/A
- ASBP N/A
- Revenue This Year
- TPST N/A
- ASBP N/A
- Revenue Next Year
- TPST N/A
- ASBP N/A
- P/E Ratio
- TPST N/A
- ASBP N/A
- Revenue Growth
- TPST N/A
- ASBP N/A
- 52 Week Low
- TPST $5.35
- ASBP $0.22
- 52 Week High
- TPST $20.67
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- TPST 63.44
- ASBP 43.63
- Support Level
- TPST $9.90
- ASBP $0.51
- Resistance Level
- TPST $11.18
- ASBP $0.59
- Average True Range (ATR)
- TPST 0.66
- ASBP 0.07
- MACD
- TPST -0.00
- ASBP -0.01
- Stochastic Oscillator
- TPST 80.69
- ASBP 21.58
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.